Table 2.
Species | Major Function | Type | Year | gRNA Promoter | Construct of Fusion Protein | PAM | Editing Window | Editing Efficiency | Multiplex Gene Editing | Applications of BEs | Off-Targets | Refs |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Industrially Important Microbes | ||||||||||||
Kluyveromyces marxianus | Industrial production of various enzymes, chemicals, and macromolecules, as well as the utilization of cell biomass | CBE | 2017 | PSNR52 | PTSNR52 | NGG | −17 to −18 | 12.5–25% | nr | Inactivate Nej1 and Dnl4 to build NHEJ null mutants with an increased efficiency of homologous recombination and to facilitate multiple integration mediated by CRISPR/Cas9 | nr | [69] |
Psedomonas spp. | An excellent bacterial host to produce polymers, bulk chemicals, drugs, and high-price specialties | CBE | 2018 | Ptrc | PrpsL-rAPOBEC1-nCas9D10A | NGG | −13 to −18 | 100% | nr | Inactivate genes in P. aeruginosa PAO1, P. putida KT2440, P. fluorescens GcM5-1A, and P. syringae DC3000 to test editing window and efficiency | nd in the six similar spacers of the rhlR and rhlB genes | [41] |
CBE | 2020 | Pj23119 | Pbs/ParaBAD-rAPOBEC1-nCas9D10A | na, none of the selected colonies achieved C-to-T mutations | [70] | |||||||
CBE | 2020 | Pj23119 | Pbs-rAPOBEC1-eSpCas9ppD10A | |||||||||
CBE | 2020 | Pj23119 | ParaBAD-rAPOBEC1-eSpCas9ppD10A | NGG | nr | 20% | nr | Edit ttgA to test editing efficiency | nr | |||
CBE | 2020 | Pj23119 | Pm-rAPOBEC1-eSpCas9ppD10A-UGI | NGG | −13 to −18 | 40–60% | nr | nr | ||||
CBE | 2020 | Pj23119 | ParaBAD-rAPOBEC1-eSpCas9ppD10A-UGI | NGG | −13 to −18 | 80–100% | 100% for double targets and 35% for triple targets | Inactivate genes in P. putida, P. aeruginosa, P. fluorescens, and P. entomophila to prove CBE general availability; simultaneously edit genes by one-plasmid and two-plasmid system | nd by Sanger sequencing the potential sites predicted by CasOT | |||
CBE | 2020 | Pj23119 | ParaBAD-rAPOBEC1-eSpCas9ppD10A-NG-UGI | NG | −13 to −18 | 100% | 100% for double targets recognized by eSpCas9pp and eSpCas9-NG in a two-plasmid system | Inactivate pykA and pcaH in one step; mutate G136 in AroF-2 to select a mutant strain with increased PCA titer up to 264.87 mg/L | nr | |||
CBE | 2020 | Pj23119 | ParaBAD-YE1-eSpCas9ppD10A-UGI | NGG | −14 to −17 | 62.5% | nr | Precisely edit ttgA, which contains multiple cytidines with enhanced editing efficiency from 25% to 62.5% | nr | |||
Yarrowia lipolytica | GRAS and industrial production of lipase and organic acids | CBE | 2019 | PSCR1’-tRNAGly | PUAS1B8-TEF(136)-nCas9D10A-PmCDA1-UGI | NGG | −14 to −20 | 28% | 6.7% for double targets | Inactivate TRP1, PEX10, HIS3 in ku70Δ strain to test editing efficiency | nr | [26] |
CBE | 2019 | PSCR1’-tRNAGly | PTEFin-nCas9D10A-PmCDA1-UGI | NGG | −14 to −20 | 94.3 ± 5% | 31% for double targets | nr | ||||
Streptomyces spp. | Industrial production of bioactive secondary metabolites, such as antifungals, antivirals, antitumorals, anti-hypertensives, and mainly antibiotics, etc. | CBE | 2019 | PermE* | PtipA-rAPOBEC1-nCas9D10A-UGI | NGG | −11 to −17 | 30–100% | 33.3% for triple targets | Substitute amino acids in SCO5087 and SCO5092; inactivate genes of BGCs in nonmodel strain S. griseofuscus; efficiently and simultaneously inactivate two identical copies of kirN | 38–56 by WGS (24–34 meaningful amino acid changes); whereas 29 SNVs in wild-type strain (18 amino acid changes); | [44] |
ABE | 2019 | PermE* | PtipA-TadA-TadA*-nCas9D10A-UGI | NGG | −12 to −17 | 0–100% | nr | Target SCO5087 and a designed matrix containing NA motifs to test efficiency and preference | 27–33 by WGS (20–21 meaningful amino acid changes) | |||
CBE | 2019 | PkasO* | PrpsL-rAPOBEC1-dCas9-UGI | NGG | −13 to −17 | 43–70% | 43% for double targets | Edit redD and actl to test C-to-T efficiency with a few C-to-G and C-to-A mutations | nr | [45] | ||
CBE | 2019 | PkasO* | PrpsL-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −17 | 100% | 100% for double targets; 60% for quintuple targets | Simultaneously disrupt the genes of polyketide synthase clusters to increase production of avermectin | 3 by Sanger sequencing the sites predicted by CasOT; | |||
CBE | 2019 | PkasO* | PrpsL-rAPOBEC1-HF-nCas9D10A-UGI | NGG | −13 to −17 | 80% | nr | Edit olm to test off-target events, which was decreased to an undetectable level | nd by Sanger sequencing the sites mentioned above | |||
ABE | 2019 | PkasO* | PrpsL-TadA-TadA*-dCas9 | na, all selected colonies showed the A/G overlapping peak in sanger sequencing | ||||||||
ABE | 2019 | PkasO* | PrpsL-TadA-TadA*-nCas9D10A | NGG | −14 to −17 | 100% | nr | Disrupt the initiation of actVB translation by converting ATG start codon to ACG to accumulate actinoperylone | nr | |||
CBE | 2019 | Pj23119 | PermEp*-dCas9-PmCDA1-UL | na, growth of cells is severely delayed when CBE was overexpressed by the strong constitutive promoter | [46] | |||||||
CBE | 2019 | Pj23119 | PtipAp-dCas9-PmCDA1-UL | NGG | −16 to 20 | 10–100% | 60% for double targets; 20% for triple targets | Inactivate genes in S. coelicolor and S.rapamycinicus to test editing efficiency and general availability to other strains | 1 by Sanger sequencing the potential sites predicted by Cas-OFFinder | |||
CBE | 2019 | Pj23119 | PtipAp-nCas9D10A-PmCDA1-UL | NGG | −16 to 20 | 15% | nr | Edit redW with low efficiency from C to T but 85% efficiency for C-to-G mutation | nr | |||
CBE | 2021 | Pgapdh (EL) | PrpsL(XC)-rAPOBEC1-dCas9-UGI | NGG | −13 to −18 | 1–20% | nr | Edit redN, redD, and act_β-ketoacyl to test editing efficiency | 16.50 ± 8.35 by WGS | [71] | ||
CBE | 2021 | Pgapdh (EL) | PrpsL(XC)-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −18 | 3–25% | nr | nr | ||||
CBE | 2021 | Pgapdh (EL) | PrpsL(XC)-rAPOBEC1-dCas9-UGI with asRNA | NGG | −13 to −18 | 21.2–65.8% | nr | 13.50 ± 3.32 by WGS | ||||
CBE | 2021 | Pgapdh (EL) | PrpsL(XC)-rAPOBEC1-nCas9D10A-UGI with asRNA | NGG | −13 to −18 | 26.2–79.4% | nr | nr | ||||
Clostridium beijerinckii | Production of acetone, n-butanol, isopropanol etc. | CBE | 2019 | Pj23119 | Pthl-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −17 | 20–100% | nr | Edit pyrE, xylR, spo0A, and araR to test efficiency of codon-optimized CBE; inactivate xylR to enhance the xylose fermentation | nr | [47] |
Clostridium ljungdahlii | Production of acetic acid and ethanol from waste gas | CBE | 2020 | Pj23119 | P2TetO1-dCas9-PmCDA1-UL | NGG | −11 to −19 | 2–55.6% | nr | Inactivate adhE1 and aor2 separately to increase acetate yield as well as lower ethanol production under either heterotrophic or autotrophic conditions | nr | [72] |
Rhodobacter sphaeroides | Industrial production of CoQ10, isoprenoids, poly-β-hydroxybutyrate, hydrogen | CBE | 2020 | Pj23119 | PLac-dCas9-PmCDA1-UL | NGG | −14 to 20 | 16.7% | nr | Inactivate appA and ppsR to test efficiency with pure C-to-T conversion | nr | [48] |
CBE | 2020 | Pj23119 | PLac-nCas9D10A-PmCDA1-UL | NGG | 14 to 20 | 10–96.7% | 43% for double targets; 46.7% for triple targets | Inactivate appA, etc., to test C-to-T efficiency with C-to-G and C-to-A byproducts; disrupt ubiF, ubiA, ubiG, and ubiX to reveal their importance in the CoQ10 biosynthetic pathway | nr | |||
ABE | 2020 | Pj23119 | PLac-TadA-TadA*-dCas9 | NGG | −14 to −16 | 0–5% | nr | Edit appA, ppsR, crtB, and bchG to alter translation level or block translation initiation | nr | |||
ABE | 2020 | Pj23119 | PLac-TadA-TadA*-nCas9D10A | NGG | −14 to −16 | 0–30% | nr | Edit appA, etc to alter translation level or block translation initiation | nr | |||
Shewanella oneidensis | Bioelectricity production from biomass wastes | CBE | 2020 | Ptac | PrpsL-rAPOBEC1-nCas9D10A | NGG | −13 to −18 | 33.3–100% | 87.5% for double targets | Target NC motifs to test editing preference; inactivate gfp, blaA, and dmsE to test editing activity; identify key genes in GlcNAc or glucose metabolism to obtain a mutant strain with enhanced degradation efficiencies for organic pollutants | nr | [49] |
Companilactobacillus crustorum | Production of bacteriocin and 3-phenyllactic acid | CBE | 2021 | P3 | PsppA-rAPOBEC1-nCas9D10A | NGG | −14 to −18 | 75–100% | nr | Edit seven C-rich spacer sequences in a plasmid to test editing window and efficiency | nr | [73] |
Agriculturally Important Microbes | ||||||||||||
Paenibacillus polymyxa | Nitrogen fixation, plant growth promotion, soil phosphorus solubilization and production of cxopolysaccharides, hydrolytic enzymes, antibiotics, and cytokinin | CBE | 2021 | Para | Pgrac-nCas9D10A-PmCDA1 | na, no transformant was obtained due to the toxicity of the fusion protein | [56] | |||||
CBE | 2021 | Para | Pspac-dCas9-PmCDA1-UGI | NGG | −16 to 20 | 100% | 100% for double and triple targets; 83.3% for quadruple targets; 75.5% for quintuple targets | Disrupt genes of five known BGCs to reveal the antimicrobial spectrum of the novel antibiotics in the sixth unknown BGCs | 8.5 SNVs including 4.2 amino acid changes by WGS | |||
Agrobacterium spp. | Nature’s genetic engineer for diverse species including crops | CBE | 2021 | Pj23119 | PaadA-dCas9-PmCDA1-UGI-LVA | na, no correct clones were obtained in E. coli probably due to the toxicity | [74] | |||||
CBE | 2021 | Pj23119 | PvirB-dCas9-PmCDA1-UL | NGG | −15 to −19 | 91% | 80% for double targets | Inactivate recA to maintain stability for plant transformation; separately inactivate rolB, rolC, and orf13 to confirm their importance in hair root construction | nr | |||
Sinorhizobium meliloti | Perform symbiotic nitrogen fixation within leguminous host plants such as alfalfa, an important forage crop | ABE | 2021 | PSigA/PRpoN/Ptyr | PHemA-TadA-TadA*-nCas9D10A | na, failed to mediate the A-to-G transition when gRNA is expressed by promoter SigA, RpoN or tyr | [75] | |||||
ABE | 2021 | PRpsT | PHemA-TadA-TadA*-nCas9D10A | NGG | −11 to −17 | 60% | nr | Edit nodA to test the editing efficiency | nr | |||
ABE | 2021 | PRpmJ | PHemA-TadA-TadA*-nCas9D10A | NGG | −11 to −17 | 100% | 90% for triple targets | Edit nodA, nodB, nodC, nifD, nifH, and nifK to test if the promoters can drive the expression of the fusion protein to perform efficient editing | nd by Sanger sequencing the potential sites predicted by Cas-OFFinder | |||
ABE | 2021 | PRpmJ | PNeo-TadA-TadA*-nCas9D10A | NGG | −11 to −17 | 100% | ||||||
ABE | 2021 | PRpmJ | PTau-TadA-TadA*-nCas9D10A | NGG | −11 to −17 | 80% | ||||||
CBE | 2021 | PRpmJ | PHemA-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −17 | 75% | nr | Inactivate nodA (W7*) to test if the growth of plants inoculated with the mutant strain was retarded | ||||
CBE | 2021 | PRpmJ | PTau-rAPOBEC1-nCas9D10A-UGI | NGG | −13 to −17 | 100% | nr | |||||
CBE | 2021 | PRpmJ | PHemA-nCas9D10A-PmCDA1-UGI | NGG | −13 to −20 | 100% | 80% for double targets; 50–70% for triple targets | Edit nodA, etc to test editing efficiency | ||||
GBE | 2021 | PRpmJ | PHemA-nCas9D10A-PmCDA1-UNG | NGG | −14 to −18 | 33–80% | nr | nr | ||||
Clinically Important Microbes | ||||||||||||
Brucella melitensis | The most important agent of human brucellosis | CBE | 2018 | PLlacO-1 | Ptrc-rAPOBEC1-nCas9D10A-UGI-NLS | NGG | −15 | 100% | nr | Inactivate virB10 by targeting three sites with 100% editing efficiency at only one site | nr | [37] |
Klebsiella pneumoniae | Cause pneumonia, bloodstream infections, wound, or surgical site infections and meningitis; biosynthesize 1,3-propanediol and 2,3-butanediol | CBE | 2018 | Pj23119 | PrpsL-rAPOBEC1-nCas9D10A | NGG | −13 to −18 | 100% | nr | Edit fosA and dhaK to test editing efficiency with a few C-to-A byproducts; inactivate the blaKPC-2 and blaCTX-M-65 to dissect drug-resistance mechanisms | nr | [60] |
Staphylococcus aureus | Cause infections ranging from skin infections to severe systemic infections | CBE | 2018 | Pcap 1A | PrpsL-rAPOBEC1-nCas9D10A | NGG | −13 to −17 | 100% | nr | Inactivate agrA and cntA to test efficiency | nr | [76] |
ABE | 2020 | Pcap 1A | PrpsL-ecTadA-TadA*-nCas9D10A | NGG | −13 to −17 | 50–100% | 100% for double targets | Screen key residues of cntBC targeted by 38 gRNAs to obtain 42 mutant strains | nd gRNA-dependent off-target by WGS | [77] | ||
Acinetobacter baumannii | causing ventilator-associated pneumonia and bloodstream infections, and mortality rates can reach 35% | CBE | 2019 | Pj23119 | Ptac-rAPOBEC1-nCas9D10A | NGG | −13 to −18 | 20–100% | nr | Edit tynA, acel, adeB, cpdA, entE, and oxyR to test editing efficiency and preference of TC motifs; disrupt drug-resistance relevant genes blaOXA-23, blaTEM-1D, and blaADC-25 to dissect drug-resistance mechanisms | nr | [78] |
Mycobacterium spp. | Causes tuberculosis, getting 10 million infections and 1.45 million deaths in 2018 worldwide | CBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9 | NNRGAA | nr | 4–15% | nr | Test availability of dSt1Cas9-BE in Mycobacterium with low efficiency for C-to-T but 18–70% efficiency for C-to-G | nr | [79] |
CBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9-UGI-UGI | NNRGAA | nr | 12–95% | nr | Inactivate katG to obtain mutant strain with increasing resistance to Isoniazid treatment | nr | |||
CBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9evolve-UGI-UGI | NNNNAA | −10 to −14 | 20–95% | 87.5% for both double and triple targets | Inactivate the essential L-leucine biosynthesis genes leuB and lueC; inactivate ctpE to increase bacterium aggregation in the presence of EGTA | nd gRNA-dependent off-target by WGS | |||
GBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9-UNG | NNRGAA | nr | 100% | nr | Edit five different loci to test editing efficiency | nr | |||
GBE | 2021 | Pj23119 | PtetR-rAPOBEC1-dSt1Cas9evolve-UNG | NNNNAA | −13 to −16 | 20–65% | 75% for triple targets | Edit 29 endogenous genomics sites to find only TC motif is available for editing | nr | |||
CBE | 2021 | Pj23119 | PtetO-rAPOBEC1-dSt1Cas9-UGI | NNAGGAC | nr | 1.2% | nr | Inactivate gfp to test editing efficiency | nr | [80] | ||
CBE | 2021 | Pj23119 | PtetO-rAPOBEC1-nSt1Cas9-UGI | NNAGGAC | nr | 10.3% | nr | nr | ||||
CBE | 2021 | Pj23119 | PtetO-rAPOBEC1-nSt1Cas9-UGI with assistant plasmid expressing recX | NNAGGAC | −12 to −18 | 37.5–100% | nr | nr | ||||
CBE | 2021 | Pj23119 | PtetO-rAPOBEC1-nSt1Cas9-UGI with assistant plasmid expressing recX and nucSE107A | NNAGGAC | nr | 12.5–75% | nr | Inavtivate Rv0582, Rv0627 and Rv2530 to test efficiency; Inactivate katG to build a mutant stain with higher 50% minimum inhibitory concentration than the wild-type strain | nr |
nr: not reported, nd: not detected, na: not available, UL: UGI-LVA (protein degradation tag), SNVs: single-nucleotide variants, WGS: whole-genome sequencing, GRAS: generally recognized as safe, BGC: biosynthetic gene cluster. The construct of BEs that failed to work in microbes are marked in red.